Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of RBD1016 in Healthy Subjects
NCT04685564Phase 1Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) and chronic hepatitis D comparing RBD1016 with Placebo (2 arms). Primary endpoints: Adverse Events and Serious Adverse Events at Day 29, 12-lead ECG at Day 29 and 3 more. Started Feb 2021; status: completed.
02
Drugs
RBD1016
03
Conditions
Chronic Hepatitis B (CHB)chronic hepatitis D
Beyond the preview
Go deeper on NCT04685564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685564.